EUCTR2006-004513-18-ES
Active, not recruiting
Not Applicable
Randomized, Double-Blind, Active- and Placebo-Controlled, Parallel Group, Multicenter Study to Evaluate the Efficacy and Safety of Multiple Doses of CG5503 Immediate Release Formulation in the Treatment of Acute Pain From Total Hip Replacement Surgery Followed by a Voluntary Open-Label ExtensionEstudio aleatorizado, en doble ciego, controlado con producto activo y con placebo, de grupos paralelos y multicéntrico, para evaluar la eficacia y la seguridad de distintas dosis de CG5503 en formulación de liberación inmediata en el tratamiento del dolor agudo consecuencia de la cirugía de artroplastia total de cadera, seguido por una extensión abierta de carácter voluntario
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.0 sites1,100 target enrollmentJuly 9, 2007
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- pain
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
- Enrollment
- 1100
- Status
- Active, not recruiting
- Last Updated
- 11 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Man or woman, between 18 to 80 years of age, inclusive
- •Signed an informed consent document indicating that they understand the purpose of and procedures required for the study and are willing to participate in the study
- •Physical status rated as \=3 on the American Society of Anesthesiologist (ASA) rating scale (see Attachment 1\)
- •Scheduled to undergo standard primary (non\-revision) unilateral total hip replacement surgery due to non\-inflammatory degenerative joint disease (NIDJD).
- •Baseline pain intensity \=4 on an 11\-point (0 to 10\) Pain Intensity NRS, rated within 30 minutes before randomization
- •Qualifying baseline pain intensity measurements occur within 6 hours of the termination of PCA (after a minimum of 12 hours of PCA), during the postoperative surgical period.
- •Must be able to complete all study related procedures and requirements throughout the study period
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1\.2 Adults (18\-64 years) yes
Exclusion Criteria
- •History of seizure disorder or epilepsy
- •Evidence of active infections that may spread to other areas of the body (e.g., osteomyelitis, pyogenic infection of the hip, Hepatitis B or C, or other overt infections) or a history human immunodeficiency virus (HIV) 1 or 2\.
- •Acute crystal\-induced arthropathy within the previous 6 months before the screening period of the study
- •Has laboratory values reflecting severe renal insufficiency indicated by a creatinine clearance \=30 mg/min.
- •Has laboratory values consistent with significant hepatic impairment based on alanine aminotransferase (ALT) or aspartate aminotransferase (AST) values greater than 3 times the upper limit of normal (ULN); or evidence of significant anemia indicated by hemoglobin (Hgb) levels \=8
- •Uncontrolled or poorly controlled post\-traumatic stress disorder generalized anxiety disorder (GAD), depression, psychiatric or other significant medical conditions
- •Treated with anticonvulsants, monoamine oxidase inhibitors, tricyclic antidepressants, neuroleptics, or serotonin norepinephrine reuptake inhibitor (SNRI) within 2 weeks before screening, (selective serotonin reuptake inhibitor \[SSRI] treatments are allowed if taken for at least 30 days before the screening period of the study at an unchanged dose)
- •Treated with a daily opioid analgesic or combination opioid analgesic, other than those containing tramadol or codeine, for more than 30 days before screening
- •Contraindications to, history of allergy to, or hypersensitivity to CG5503, Oxycodone, hydromorphone, morphine, or fentanyl, or their excipients.
- •Systemic steroid therapy within 3 months before screening, excluding inhalers or a 1\-time intraoperative dose
Outcomes
Primary Outcomes
Not specified
Similar Trials
Active, not recruiting
Phase 1
Randomized, Double-Blind, Active- and Placebo-Controlled, Parallel Group, Multicenter Study to Evaluate the Efficacy and Safety of Multiple Doses of CG5503 Immediate Release Formulation in the Treatment of Acute Pain From Total Hip Replacement Surgery Followed by a Voluntary Open-Label ExtensiopainMedDRA version: 8.1Level: LLTClassification code 10033371Term: PainEUCTR2006-004513-18-FRJohnson & Johnson Pharmaceutical Research & Development, L.L.C.
Active, not recruiting
Not Applicable
Randomized, Double-Blind, Active- and Placebo-Controlled, Parallel Group, Multicenter Study to Evaluate the Efficacy and Safety of Multiple Doses of CG5503 Immediate Release Formulation in the Treatment of Acute Pain From Total Hip Replacement Surgery Followed by a Voluntary Open-Label ExtensioEUCTR2006-004513-18-FIJohnson & Johnson Pharmaceutical Research & Development, L.L.C.1,100
Active, not recruiting
Phase 1
Randomized, double-blind, placebo and active controlled study of the activity ofSAR407899A single-dose on the ability to increase duration of penile rigidity,under experimental condition, in patients with mild to moderate erectiledysfunction - RHOKETMild to moderate erectile dysfunctionMedDRA version: 11.1Level: LLTClassification code 10061461Term: <Manually entered code. Term in E.1.1>EUCTR2009-009936-56-FRsanofi-aventis recherche et développement24
Active, not recruiting
Not Applicable
Clinical trial to evaluate the clinical effect and safety of a triple combination of ibuprofen, magnesium and vitamin C in the treatment of acute pain in temporomandibular disorders (TMD).Temporomandibular joint dysfunction syndrome.Therapeutic area: Diseases [C] - Mouth and tooth diseases [C07]EUCTR2014-003790-41-ESSpherium Biomed
Suspended
Not Applicable
Safety, tolerability, pharmacokinetic (PK) and pharmacodynamic (PD) study with ENX-201Multiple Sclerosis (relapses)NL-OMON23997EnhanX Biopharm Inc.12